ABERDEEN, Scotland and Singapore, 25th January, 2018 – TauRx Therapeutics Ltd has reported preclinical study results, published online in Frontiers in Molecular Neuroscience, showing that LMTM, the active pharmaceutical ingredient in its LMTX® product originally developed for the treatment of Alzheimer’s disease, may also be useful for the treatment of Parkinson’s disease (PD).1
Results from this study in a transgenic model of PD show that LMTM, developed as the first tau aggregation inhibitor for treatment of Alzheimer’s disease, may also provide a potential disease-modifying therapy in PD and other synucleinopathies. LMTM works by dissolving and preventing further aggregation of the proteins that are closely linked to neurodegeneration in these diseases. Accumulation of an aggregated form of alpha-Synuclein protein (αSyn) in brain cells is closely associated with PD and also with dementia with Lewy bodies (LBD).2 In the PD form, movement is primarily affected, whereas in LBD the pathology causes hallucinations and progressive dementia.
Read more here.
TauRx Therapeutics Ltd has reported preclinical study results published online in Frontiers in Molecular Neuroscience showing that LMTM may also be useful for the treatment of Parkinson’s disease (PD)
